Document is current
Any future updates will be listed below
-
Authors
Ando, Koji https://orcid.org/0000-0002-0149-1505
Satake, Hironaga
Shimokawa, Mototsugu
Yasui, Hisateru
Negoro, Yuji
Kinjo, Tatsuya
Kizaki, Junya
Baba, Kenji
Orita, Hiroyuki
Hirata, Keiji
Sakamoto, Sanae
Makiyama, Akitaka
Saeki, Hiroshi
Tsuji, Akihito
Baba, Hideo
Oki, Eiji https://orcid.org/0000-0002-9763-9366
-
Funding
Funding for this research was provided by:
Sanofi K.K.
- License Information
-
More Information
Article History
Received: 10 September 2024
Accepted: 9 January 2025
First Online: 1 February 2025
Declarations
:
: KA, MS, HY, YN, TK, KT, KB, HO, KH and SS declare no conflicts of interest. HSatake has received research funding from AsahiKASEI Co. Ltd., Ono Pharmaceutical Co. Ltd., Daiichi Sankyo, Taiho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd. and Sanofi, honoraria from Bayer Co., Ltd., Bristol-Myers Squibb Co., Ltd., Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Eli Lilly Japan Co., Ltd., Merck Bio Pharma Co., Ltd., MSD Co., Ltd., Ono Pharmaceutical Co., Ltd., Sanofi Co., Ltd., Taiho Pharmaceutical Co., Ltd., Takeda Co., Ltd. and Yakult Honsha Co., Ltd. AM received honoraria from Eli Lilly, Japan K.K.; Taiho Pharmaceutical Co., Ltd.; Ono Pharmaceutical Co., Ltd.; Bristol-Myers Squibb Co., Ltd.; and Daiichi Sankyo Co., Ltd. HS received research funding from Taiho Pharmaceutical Co. Ltd. and Chugai Pharmaceutical Co. Ltd.. AT received honoraria for lectures from ELI LILLY JAPAN K.K., TAIHO PHARMACEUTICAL CO., LTD., ONO PHARMACEUTICAL Co., Ltd., CHUGAI PHARMACEUTICAL Co., Ltd., Merck Biopharma Co., Ltd., NOVARTIS PHARMA K.K., TAKEDA PHARMACEUTICAL COMPANY LIMITED, DAIICHI SANKYO CO., LTD, MSD K.K., TSUMURA & Co., AstraZeneca K.K., Sun Pharmaceutical Industries Limited, ASAHI KASEI PHARMA CORPORATION. HB received scholarship grants from Eli Lilly Japan and K.K. EO received research funding from Guardant Health and honoraria for lectures from Ono, Takeda, Bayer, Chugai, Taiho, Eli Lilly, and Bristol Myers Squibb.
: Approval of the research protocol by an Institutional Reviewer Board: Before the initiating the study, the principal investigator consulted a Certified Review Board (certification no. CRB718005), received approval from the study site manager, and submitted a trial plan to the Ministry of Health, Labour, and Welfare.
: This study was conducted in accordance with the Good Clinical Practice guidelines and guiding principles detailed in the Declaration of Helsinki and in keeping with the applicable local law(s) and regulations (s). Written informed consent for the study procedures was provided by all candidate patients before enrolment.
: This study was registered with the Japan Registry of Clinical Trials (registration number: jRCTs071190003).
: Not applicable.
